Back to top

Analyst Blog

Zacks Equity Research

Medivation Impresses with MDV3100


 ZacksTrade Now

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at or call 800-767-3771 ext.  9339.

Medivation, Inc. (MDVN - Analyst Report) and partner Astellas Pharma Inc. announced positive survival data on their phase III prostate cancer candidate, MDV3100. Medivation and Astellas said that results from a planned interim analysis showed a statistically significant improvement in overall survival compared to placebo. The interim analysis was conducted at 520 events.

The phase III randomized, double-blind, placebo-controlled study, AFFIRM, was conducted in men with advanced prostate cancer previously treated with docetaxel-based chemotherapy.

The interim data is impressive with MDV3100 showing a 4.8-month advantage in median overall survival compared to placebo (18.4 months versus 13.6 months). A 37% reduction in risk of death was observed in the MDV3100 arm compared to placebo.

Based on the positive interim data, the Independent Data Monitoring Committee (IDMC) recommended that AFFIRM should be stopped early and patients in the placebo arm should be offered MDV3100. The IDMC said that MDV3100's risk-to-benefit ratio was favorable enough to stop the study.

A full analysis of the results including safety data will be presented at an upcoming scientific meeting.

Medivation and Astellas intend to conduct a pre-NDA meeting with the FDA early next year. We expect to gain more visibility on the regulatory path for the candidate on the conclusion of this meeting.

In addition to the AFFIRM study, MDV3100 is currently in another phase III study, PREVAIL, which is being conducted in men with advanced prostate cancer who have not received chemotherapy. Two phase II studies are also in progress. While one study, TERRAIN, is being conducted in men whose disease has progressed while on luteinizing hormone releasing hormone (LHRH) analogue or hormone therapy, the other phase II study is being conducted in hormone-naïve men.

Outperform on Medivation

We have an Outperform recommendation on Medivation, which carries a Zacks #1 Rank (short-term Strong Buy rating). Medivation shares received a major boost on the positive MDV3100 data. Based on the data that we have seen so far, we believe MDV3100 has blockbuster potential.

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
BITAUTO HOLD BITA 35.33 +14.82%
ANI PHARMACE ANIP 24.79 +14.66%
E HOUSECHINA EJ 10.99 +9.24%
CANADIAN SOL CSIQ 26.97 +7.15%